GET DAILY SIGNALSWhy Is Faeth Therapeutics (FTH) Stock Down -5.13% Today?
Key Takeaways
- Faeth Therapeutics (FTH) shares fell 5.13% to $12.03, extending Monday's sharp selloff.
- The decline is a continuation of the market reaction to Phase 2 PIK-201 topline data for its lead program, PIKTOR, in advanced endometrial cancer.
- A confirmed objective response rate of 33% and a 64% rate of Grade 3 or higher adverse events drove efficacy and tolerability concerns, despite an 83% disease control rate.
- Several sell-side analysts called the initial plunge "overdone" and reiterated Buy ratings, arguing the data support Phase 3 development.
- Broader equity markets traded mixed, with FTH underperforming biotech peers on continued selling pressure.
- Traders are watching analyst commentary, Phase 3 trial design updates, and any financing developments.
- For deeper analysis, explore Faeth's Price Targets, Earnings, and Forecast pages.
- For AI-driven trading ideas across the market, explore Trending AI Robots.
Opening Summary
Faeth Therapeutics, Inc. (FTH), a clinical-stage oncology company based in Austin, Texas, saw its stock fall 5.13% on Tuesday to $12.03, down from a prior close of $12.68. The decline extends a dramatic selloff that began Monday, when shares plunged more than 40% after the company reported preliminary Phase 2 topline results for PIKTOR in combination with paclitaxel in patients with advanced endometrioid endometrial cancer. While management framed the data as positive, investors focused on the headline response rate and safety profile, triggering sustained downward pressure that carried into today's session.
Catalyst Breakdown: Phase 2 PIK-201 Data Reaction
The primary driver behind today's move is the continuing market digestion of the PIK-201 trial results. Faeth reported a confirmed objective response rate (ORR) of 33% — 12 of 36 efficacy-evaluable patients — along with a disease control rate of 83% and a preliminary median progression-free survival of 7.4 months. The company noted a higher 44% ORR among patients with PIK3CA mutations and said the data support advancing PIKTOR into a Phase 3 registrational trial.
Despite those figures, the market reacted bearishly. Investors questioned whether the headline response rate is sufficiently differentiated from emerging antibody-drug conjugates and other standard-of-care options in the same setting. The trial was single-arm with no comparator, making relative efficacy difficult to establish, and six patients were excluded from the efficacy analysis. These uncertainties extended Monday's rout into Tuesday's trading.
Safety Profile Adds to Investor Caution
Compounding the efficacy debate, the safety data drew scrutiny. A total of 64% of treated patients experienced Grade 3 or higher treatment-related adverse events, with neutropenia the most frequent severe toxicity. While Faeth emphasized that hyperglycemia and stomatitis were mostly low grade and that there were no treatment-related deaths, the elevated rate of serious adverse events added to concerns about the regimen's commercial viability in a broader, heavily pretreated patient population.
Analyst Defense and Contrarian Commentary
Several analysts pushed back against the selloff, arguing the market overreacted. H.C. Wainwright reiterated a Buy rating and a $60 price target, calling the decline "overdone" and noting the 33% ORR fell within its previously outlined 30%–40% success benchmark. Lucid Capital maintained a Buy rating with a $59 target, describing the selloff as "disproportionate" to the data. BTIG and Leerink Partners also framed the results as within expectations. This split between analyst support and investor skepticism has fueled volatility, but the near-term momentum remained negative on Tuesday.
Market Context and Trading Activity
Trading volume surged dramatically relative to the stock's recent average. Monday's session recorded roughly 2.1 million shares changing hands, compared with around 100,000 to 130,000 shares on typical recent days, signaling broad-based distribution. Tuesday's activity reflected continued elevated selling pressure as the stock traded near the lower end of its recent range, having touched an intraday low of about $10.45 the prior day. The move diverged from the broader market, where major indices traded mixed, underscoring that the decline was company-specific rather than sector-wide. Technically, the shares broke decisively below prior support levels and short-term moving averages, leaving the stock in a clearly bearish near-term posture.
What Comes Next for FTH
Looking ahead, the focus for FTH shifts to regulatory alignment and trial design. Faeth plans to advance PIKTOR into a Phase 3 registrational study, subject to discussions with regulators, with pivotal trial design details expected in the first half of 2027. Investors will also monitor early safety and efficacy data from the PIK-101 program in HR+/HER2- breast cancer, expected in 2027. The company ended its most recent quarter with roughly $174.8 million in cash and marketable securities, providing a meaningful runway, though a Phase 3 program will require substantial additional investment. Key risks include the single-arm nature of the Phase 2 data, the competitive landscape in endometrial cancer, and potential financing needs as development advances.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, giving traders a focused view of which automated strategies are working right now. Explore the Trending AI Robots to see how AI-driven strategies are navigating today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
FTH in upward trend: price may jump up because it broke its lower Bollinger Band on November 09, 2026
FTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where FTH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTH advanced for three days, in 169 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 45 cases where FTH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTH as a result. In 84 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for FTH turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for FTH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. FTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.294) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement